Antipsychotics in the treatment of schizophrenia: An overview

Journal of Clinical Psychiatry

Volumn 72, Issue SUPPL. 1, 2011, Pages 4-8

  Tandon, Rajiv ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; COGNITIVE THERAPY; COMPARATIVE EFFECTIVENESS; DEPOLARIZATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DISORIENTATION; DOPAMINE RECEPTOR BLOCKING; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL DISEASE; HEALTH CARE QUALITY; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HORMONE BLOOD LEVEL; HUMAN; HYPOTENSION; LONG TERM CARE; METABOLIC DISORDER; METABOLIC SYNDROME X; MOOD DISORDER; MORTALITY; NEGATIVE SYNDROME; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOCIAL ADAPTATION; SOCIAL STATUS; TARDIVE DYSKINESIA; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 84555202698     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10075su1.01     Document Type: Review

References (58)

1. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008, pt 1: overview. Schizophr Res. 2008;100(1-3): 4-19. doi:10.1016/j.schres.208.01.02 PubMed
2. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151(10):1409-1416. PubMed (Pubitemid 24301683)
3. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts," 4: clinical features and conceptualization. Schizophr Res. 2009;110(1-3):1-23. doi:10.1016/j.schres.209.03.05 PubMed
4. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123-1131. doi:10.101/archpsyc.64.10.123 PubMed (Pubitemid 47529346)
5. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts,"1: what we know in 2008, 2: epidemiology and etiology. Schizophr Res. 2008;102(1-3):1-18. doi:10.1016/j.schres.208.04.01 PubMed
6. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts,"5: treatment and prevention: past, present, and future. Schizophr Res. 2010;122(1-3):1-23. doi:10.1016/j.schres.2010.05.025 PubMed
7. Delay J, Deniker P, Karl J. Traitement des etats d'excitation et d'agitation par une methode medicamenteuse derive de l'hibernotherapie. Ann Medicopsychol. 1952;119:267-273.
8. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50(11):873-883. doi:10.1016/S06-323(01)01251-3 PubMed (Pubitemid 34020700)
9. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a doubleblind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520. doi:10.176/api.ajp.157.4.514 PubMed (Pubitemid 30191189)
10. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis - linking biology, pharmacology and phenomenology of psychosis. Schizophr Res. 2005;79(1):59-68. doi:10.1016/j.schres.205.01.03 PubMed (Pubitemid 41362593)
11. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006;163(4):743-745. doi:10.176/api.ajp.163.4.743 PubMed (Pubitemid 44464590)
12. Leucht S, Busch R, Hamann J, et al. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005;57(12):1543-1549. doi:10.1016/j.biopsych.205.02.023 PubMed (Pubitemid 40805384)
13. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2003;28(suppl 1):9-26. doi:10.1016/S0306-4530(02)010-5 PubMed
14. Nasrallah HA, Tandon R. Classic antipsychotic medications. In: Nemeroff C, Schatzberg A, eds. American Psychiatric Press Textbook of Psychopharmacology. 4th ed. Washington, DC: American Psychiatric Press; 2009:533-554.
15. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796. PubMed
16. Meltzer HY, Alphs L, Green AI, et al.; International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91. doi:10.101/archpsyc.60.1.82 PubMed
17. Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa05168 PubMed
18. Keefe RS, Bilder RM, Davis SM, et al.; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633-647. doi:10.101/archpsyc.64.6.63 PubMed
19. Rankupalli B, Tandon R. Practicing evidence-based psychiatry, 1: applying a study's findings: the threats to validity approach. Asian J Psychiatr. 2010;3(1):35-40. doi:10.1016/j.ajp.2010.01.02
20. Kahn RS, Fleischhacker WW, Boter H, et al.; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097. doi:10.1016/S0140-6736(08)60486-9 PubMed
21. Kane JM, Leucht S, Carpenter D, et al.; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The Expert Consensus Guideline Series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5-19. PubMed
22. Tandon R, Belmaker RH, Gattaz WF, et al.; Section of Pharmacopsychiatry, World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100(1-3):20-38. doi:10.1016/j.schres.207.1.03 PubMed
23. Adams CE, Coutinho E, Davis JM, et al. Cochrane Schizophrenia Group publications. The Cochrane Library. Chichester, United Kingdom: John Wiley and Sons; 2009 (szg.cochrane.org, accessed July 19, 2011).
24. Leucht S, Barnes TRE, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209-1222. doi:10.176/api.ajp.160.7.1209 PubMed
25. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41. doi:10.1016/S0140-6736(08)61764-X PubMed
26. Hugenholtz GW, Heerdink ER, Stolker JJ, et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry. 2006;67(6):897-903. doi:10.408/JCP.v67n0606 PubMed
27. Haj-Ibrahim J, Tandon R. Practicing evidence-based psychiatry, 2: interpreting integrative literature: systematic reviews and meta-analyses. Asian J Psychiatr. 2011;4(1):80-85. doi:10.1016/j.ajp.201.02.04
28. Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? a meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429-447. doi:10.1038/sj.mp.402136 PubMed
29. McEvoy JP, Lieberman JA, Stroup TS, et al.; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610. doi:10.176/api.ajp.163.4.60 PubMed
30. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158(4):518-526. doi:10.176/api.ajp.158.4.518 PubMed
31. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163. doi:10.176/api.ajp.208. 08030368 PubMed
32. Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for firstepisode schizophrenia: a comparative review. CNS Drugs. 2009;23(10):837-855. doi:10.2165/1314280-0-0 PubMed
33. Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35(2):581-590. doi:10.1038/np.209. 164 PubMed
34. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand. 2007;115(1):4-11. doi:10.1/j.160-047. 206.0947.x PubMed
35. Tandon R, Ribeiro SCM, DeQuardo JR, et al. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol Psychiatry. 1993;34(7):495-497. doi:10.1016/06-323(93)90242-6 PubMed
36. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl). 2004;171(2):121-132. doi:10.107/s0213-03-1648-y PubMed
37. Hill SK, Bishop JR, Palumbo D, et al. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother. 2010;10(1):43-57. doi:10.1586/ern.09.143 PubMed
38. Adams CE, Fenton MKP, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179(4):290-299. doi:10.192/bjp.179.4.290 PubMed
39. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. PubMed
40. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158(11):1774-1782. doi:10.176/api.ajp.158.1.174 PubMed
41. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-2314. doi:10.2165/03495-2046420-03 PubMed
42. Kane JM. Tardive dyskinesia circa 2006. Am J Psychiatry. 2006;163(8):1316-1318. doi:10.176/api.ajp.163.8.1316 PubMed
43. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51(8):480-491. PubMed
44. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13(1):13-24. doi:10.1097/0131746-207010-03 PubMed
45. Smith M, Hopkins D, Peveler RC, et al. First- v second- generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008:192:406-411.
46. Ozbilen M, Adams CE. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol. 2009;29(2):141-146. doi:10.1097/JCP.0b013e31819a91f1 PubMed
47. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235. doi:10.1056/NEJMoa080694 PubMed
48. Fischer-Barnicol D, Lanquillon S, Haen E, et al.; Working Group 'Drugs in Psychiatry.' Typical and atypical antipsychotics - the misleading dichotomy: results from the Working Group 'Drugs in Psychiatry' (AGATE). Neuropsychobiology. 2008;57(1-2):80-87. doi:10.159/0135641 PubMed
49. Ran MS, Chan CL-W, Chen EY-H, et al. Differences in mortality and suicidal behaviour between treated and never-treated people with schizophrenia in rural China. Br J Psychiatry. 2009;195(2):126-131. doi:10.192/bjp.bp.108. 05301 PubMed
50. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627. doi:10.1016/S0140-6736(09)60742-X PubMed
51. De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? a critical appraisal of the FIN-11 study. Schizophr Res. 2010;117(1):68-74. doi:10.1016/j.schres.209.12.029 PubMed
52. Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nation-wide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224. doi:10.136/bmj.381. 38275.2F PubMed
53. Thirthalli J, Venkatesh BK, Kishorekumar KV, et al. Prospective comparison of course of disability in antipsychotic-treated and untreated schizophrenia patients. Acta Psychiatr Scand. 2009;119(3):209-217. doi:10.1/j.160-047.208.0129.x PubMed
54. Dixon LB, Dickerson F, Bellack AS, et al.; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):48-70. doi:10.1093/schbul/sbp15 PubMed
55. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-457. doi:10.1093/schbul/sbn018 PubMed
56. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272. doi:10.408/JCP.v65n0219 PubMed
57. Tandon R, Targum SD, Nasrallah HA, et al.; Treatment Effectiveness in Schizophrenia Consortium. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Pract. 2006;12(6):348-363. doi:10.1097/0131746-20610-03 PubMed
58. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334-1349. doi:10.176/api.ajp.